Ameriprise
VRDN icon

Ameriprise’s Viridian Therapeutics VRDN Stock Holding History

Ameriprise’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$446K Sell
22,781
-352
-2% -$10.5K ﹤0.01% 3628
2025
Q4 		$720K Buy
23,133
+95
+0.4% +$2.61K ﹤0.01% 3482
2025
Q3 		$497K Sell
23,038
-93
-0.4% -$1.68K ﹤0.01% 3628
2025
Q2 		$323K Sell
23,131
-35,140
-60% -$477K ﹤0.01% 3670
2025
Q1 		$785K Buy
58,271
+9,478
+19% +$161K ﹤0.01% 3303
2024
Q4 		$935K Buy
48,793
+6,806
+16% +$148K ﹤0.01% 3269
2024
Q3 		$955K Buy
41,987
+21,002
+100% +$343K ﹤0.01% 3240
2024
Q2 		$273K Buy
+20,985
New +$290K ﹤0.01% 3612
2023
Q1 		– Sell
-267,765
Closed -$7.82M – 4038
2022
Q4 		$7.82M Buy
+267,765
New +$6.17M ﹤0.01% 1952

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return